Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
By P. Teismann, K. Tieu, D. Choi, D. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, S. Przedborski. Proceedings of the National Academy of Sciences of the United States of America, 2003
669 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/53ff7f9000972f5968a288bc78bb71b4e2a777bb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pharmacology
Citations in the corpus
- Cyclooxygenase‐2 (COX‐2) in Inflammatory and Degenerative Brain Diseases (2004, background): “In some cases, neuroprotection has been related to free radical scavenging effects rather then to COX inhibition or attenuation of inflammation (51, 52).”
- Selective COX-1 inhibition: A therapeutic target to be reconsidered. (2010, background): “predominant role of this isoform in PGE2 synthesis during MPTP-induced neurodegeneration [73].”
- Inflammation as a causative factor in the aetiology of Parkinson's disease (2007, background): “However, the neuroprotective effect of COX-2 inhibitors against MPTP in vivo may not be due to the reduced microglial activation, but rather has been linked to inhibition of COX-induced DA oxidation (Teismann et al., 2003a, b).”
- Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. (2008, background): “shown that the selective COX-2 inhibitor paracoxib exhibits neuroprotective activity in animal models of PD (74, 75).”